SAIC-Frederick, Inc. And Roche Applied Science Enter into a Research Collaboration on Technology Advancements for Cancer Gene Sequencing

MADISON, Wis.--(BUSINESS WIRE)--National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (NYSE: SAI), and Roche Applied Science, a division of Roche Diagnostics Corporation (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY), have signed a collaboration agreement to assess Roche’s advanced technologies to sequence the genomes of cancer research samples. These technologies include targeted enrichment with NimbleGen Sequence Capture and ultra-deep sequencing using the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company. With these technologies, Roche Applied Science provides a complete solution for targeted re-sequencing of the human genome to further our understanding of disease associated regions.